SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?


To: mopgcw who wrote (2527)10/28/2005 10:47:33 AM
From: Icebrg  Respond to of 3044
 
Having seen the difficulties Velcade has had penetrating into second- and now firstline treatment of MM without a proper labeling, I believe that the off-label use of Revlimid in MM based on its MDS-label will be limited. And if there is such a penetration it will most likely hit Thalidomide rather than Velcade to start with.

Erik